Caladrius Biosciences Inc.

(CLBS) Trade

By |

Profile

Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A. For more information on the company, please visit www.caladrius.com

Contact Information

Website: www.caladrius.com
Email: jmenditto@caladrius.com
Main Phone: +1 908 842-0100
Address: 110 Allen Road
Address 2: 2nd Floor
State: NJ
City / Town: Basking Ridge
Country: US
Postal Code: 07920

Issuer Information

Exchange: NSC
CEO: David J. Mazzo
Employees: 27
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

Profile

Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A. For more information on the company, please visit www.caladrius.com

Contact Information

Website: www.caladrius.com
Email: jmenditto@caladrius.com
Main Phone: +1 908 842-0100
Address: 110 Allen Road
Address 2: 2nd Floor
State: NJ
City / Town: Basking Ridge
Country: US
Postal Code: 07920

Issuer Information

Exchange: NSC
CEO: David J. Mazzo
Employees: 27
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

$ 1.70 $ -0.12 (-6.59%)
Last Price 1.70 Change $ -0.12 Change % -6.59 Tick N/A
Bid 1.71 Bid Size 1,000.00 Ask 1.75 Ask Size 1,000.00
Open 1.83 High 1.88 Low 1.62 Prev Close 1.82
Last Trade Volume 309,335 52 Wk Hi 3.65 52 Wk Low 1.05
Market Cap 32.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 19,323,107.00 EPS (TTM) -0.83 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 7
Number of Buys 0 4
Number of Sells 0 3
Net Activity 0 101014
Last 10 Buys Shares
David J. Mazzo 1,000
Robert S. Vaters 1,000
Robert S. Vaters 1,000
Steven S. Myers 1,000
Steven S. Myers 1,000
Steven S. Myers 1,000
Steven S. Myers 1,000
Steven M. Klosk 1,000
Steven S. Myers 1,000
Steven S. Myers 1,000
Last 10 Sell Shares
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
Eric H.C. Wei 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 12 12 12 12
Low Target Price Estimate 7 7 7 7
Mean Target Price Estimate 9.5 9.5 9.5 9.5
Standard Deviation 3.54 3.54 3.54 3.54
Date of Most Recent Estimate 05/22/18 05/22/18 05/22/18 05/22/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1